The board chairman of Chinese pharmaceutical company Hunan Fangsheng Pharmaceutical Co., Ltd has been fined 600,000 yuan. (~€77,000/~$91,000) in an insider trading case. Chinese officials started investigating the company in June 2019 following a rise in Fangshen shares the previous April when the company announced it had signed a cooperation agreement with the government of Huize County, Yunnan, to develop hemp farming and processing operations. The company later admitted in a subsequent announcement that the project was still in the planning phase and faced uncertainty, causing Fangshen’s stock to fall sharply.
Chinese exec fined for insider trading
Support HempToday with a donation
We appreciate our paying subscribers and strive to deliver the most complete, well-researched and comprehensive news, analysis and commentary about the hemp industries. If you’d like to further support us, click below to make a donation.